| Study Protocol Number | Study Title and Description |
|---|---|
| 26-0037 |
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms |
| 23-1917 |
CCTG-NE1: A PHASE II STUDY OF 177LUTETIUM-DOTATATE RETREATMENT VS. EVEROLIMUS OR SUNITINIB OR CABOZANTINIB IN METASTATIC/UNRESECTABLE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOURS
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus in patients who have previously received 177Lu-DOTATATE for midgut neuroendocrine tumor (NET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surge... |